Evidence map›Paper›PMID 24457522›Full record

ArticleMolecular psychiatry2014

DISC1 as a genetic risk factor for schizophrenia and related major mental illness: response to Sullivan.

D J Porteous, P A Thomson, J K Millar, K L Evans, W Hennah, D C Soares, S McCarthy, W R McCombie, S J Clapcote, C Korth and 8 more

Abstract readEditorialComment
In one paragraph

Article in Molecular psychiatry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Mutations in DISC1 alter IPNeuronal signaling · 2021
    Review
  5. Article
  6. Article
  7. Disorder Mediated Oligomerization ofThe journal of physical chemistry. B · 2019
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Recent Advances in the Genetics of Schizophrenia.Molecular neuropsychiatry · 2018
    Review
  17. Article
  18. Using mouse transgenic and human stem cell technologies to model genetic mutations associated with schizophrenia and autism.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2018
    Review
  19. TheOpen biology · 2017
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

D J PorteousCentre for Genomic and Experimental Medicine, MRC/University of Edinburgh Institute of Genetics & Molecular Medicine, Western General Hospital, Edinburgh, UK.
P A ThomsonCentre for Genomic and Experimental Medicine, MRC/University of Edinburgh Institute of Genetics & Molecular Medicine, Western General Hospital, Edinburgh, UK.
J K MillarCentre for Genomic and Experimental Medicine, MRC/University of Edinburgh Institute of Genetics & Molecular Medicine, Western General Hospital, Edinburgh, UK.
K L EvansCentre for Genomic and Experimental Medicine, MRC/University of Edinburgh Institute of Genetics & Molecular Medicine, Western General Hospital, Edinburgh, UK.
W HennahInstitute for Molecular Medicine Finland FIMM, Biomedicum Helsinki 2U, Helsinki, Finland.
D C SoaresCentre for Genomic and Experimental Medicine, MRC/University of Edinburgh Institute of Genetics & Molecular Medicine, Western General Hospital, Edinburgh, UK.
S McCarthyCold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.
W R McCombieCold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.
S J ClapcoteSchool of Biomedical Sciences, University of Leeds, Leeds, UK.
C KorthDepartment of Neuropathology, Heinrich Heine University, Moorenstraße 5, Dusseldorf, Germany.
N J BrandonAstraZeneca Neuroscience iMed, Cambridge, MA, USA.
A SawaJohns Hopkins Schizophrenia Center, Department of Psychiatry Molecular Psychiatry Program, Department of Mental Health, Johns Hopkins University, School of Medicine and Bloomberg School of Public Health, Baltimore, MD, USA.
A KamiyaDepartment of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
J C RoderLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Joseph & Wolf Lebovic Health Complex, Toronto, Ontario, Canada.
S M LawrieDivision of Psychiatry, School of Clinical Sciences, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK.
A M McIntoshDivision of Psychiatry, School of Clinical Sciences, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK.
D St ClairInstitute of Medical Sciences University of Aberdeen, Aberdeen, UK.
D H BlackwoodInstitute of Medical Sciences University of Aberdeen, Aberdeen, UK.

Funding

Project 3P50MH094268 · NIMH · JOHNS HOPKINS UNIVERSITY · PI SAWA, AKIRA · 2011 to 2020
$19.9M
Medical Research Council G0100266Medical Research Council G0600214Medical Research Council G0902166Medical Research Council MR/J004367/1Medical Research Council MR/K026992/1NIMH NIH HHS P50 MH094268
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

HumansNerve Tissue ProteinsSchizophreniaNerve Tissue Proteins

Identifiers

PMID24457522
PMCPMC4238281

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.